DISKHALER for Delivery to
the Respiratory Tract

Drug delivery to site of influenza viral infection
and replication [10]

RELENZA is deposited throughout the respiratory tract

• Post-dosing scan of RELENZA was obtained within one minute of inhalation
• The correlation between imaging and clinical results has not been established

Study Characteristics

• A study of 13 healthy volunteers in Nottingham, England
• The deposition values included: oropharynx (77.6%) and whole lung (13.2%)
• Drug distribution imaging and study data, while relevant to prophylactic use of RELENZA in healthy adults with normal airways, may be markedly different in patients with airway disease, including that due to influenza. [10]

next: About the DISKHALER

Important Safety Information RELENZA IS NOT RECOMMENDED FOR TREATMENT OR PROPHYLAXIS OF INFLUENZA IN INDIVIDUALS WITH UNDERLYING AIRWAY DISEASE (SUCH AS ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE). Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airway disease. Many of these cases were reported during postmarketing, and causality was difficult to assess RELENZA SHOULD BE DISCONTINUED IN ANY PATIENT WHO DEVELOPS BRONCHOSPASM OR DECLINE IN RESPIRATORY FUNCTION; immediate treatment and hospitalization may be required RELENZA has not been proven effective for treatment of influenza in individuals with underlying airways disease. Patients should be instructed in the use of the delivery system. Instructions should include a demonstration whenever possible If treatment with RELENZA is considered for a patient with underlying airway disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators Common adverse events in treatment and prophylaxis studies with RELENZA were nausea, diarrhea, sinusitis, viral respiratory infections, headaches, nasal signs and symptoms. The incidence of these adverse events was similar in both groups for RELENZA and placebo-treated groups Click here for Complete Prescribing Information for RELENZA.